Schizophrenia and Disorders with Psychotic Features  >>  Invega Sustenna (paliperidone palmitate extended-release 1-month injection)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
NCT01606254: A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia

Completed
2
56
Japan
Paliperidone palmitate, JNS010
Janssen Pharmaceutical K.K.
Schizophrenia
04/08
04/08
NCT01450514 / 2011-004494-81: POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia

Completed
2
7
Europe
Pipamperone, Risperdal, Invega and Xeplion, Placebo
PharmaNeuroBoost N.V.
Chronic Schizophrenia, Schizoaffective Disorder
11/12
12/12

Download Options